Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry General industrial machinery,
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EKSO
CUSIPN/A
Phone510-984-1761
Debt
Debt-to-Equity Ratio0.29
Current Ratio2.79
Quick Ratio2.50
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.35 million
Price / Sales14.44
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book4.89
Profitability
EPS (Most Recent Fiscal Year)($0.89)
Net Income$-29,120,000.00
Net Margins-340.49%
Return on Equity-184.66%
Return on Assets-94.96%
Miscellaneous
Employees92
Outstanding Shares60,350,000
Market Cap$106.16
Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions
What is Ekso Bionics' stock symbol?
Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."
When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?
Shares of Ekso Bionics reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.
How were Ekso Bionics' earnings last quarter?
Ekso Bionics Holdings Inc (NASDAQ:EKSO) announced its quarterly earnings results on Monday, May, 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.03. The business earned $2.52 million during the quarter, compared to analyst estimates of $2.98 million. Ekso Bionics had a negative net margin of 340.49% and a negative return on equity of 184.66%. View Ekso Bionics' Earnings History.
What is the consensus analysts' recommendation for Ekso Bionics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Ekso Bionics' key competitors?
Some companies that are related to Ekso Bionics include Antares Pharma (ATRS), Neuronetics (STIM), OrganiGram (OGRMF), Evelo Biosciences (EVLO), Albireo Pharma (ALBO), Georgia Healthcare Group (GHG), American Brivision (Holding) (ABVC), Pharma Mar (PHMMF), Syros Pharmaceuticals (SYRS), Concert Pharmaceuticals (CNCE), Clementia Pharmaceuticals (CMTA), MediGene (MDG1), Savara (SVRA), GenMark Diagnostics (GNMK) and PDL BioPharma (PDLI).
Who are Ekso Bionics' key executives?
Ekso Bionics' management team includes the folowing people:
- Mr. Jack Peurach, Pres, CEO & Director (Age 52)
- Mr. Maximilian Scheder-Bieschin, Chief Financial Officer (Age 56)
- Mr. Russell L. DeLonzor, Chief Operating Officer (Age 56)
- Ms. Foon Lim Chwee, Pres of APAC
- Mr. Darrell Musick, VP of Clinical
Has Ekso Bionics been receiving favorable news coverage?
Media headlines about EKSO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ekso Bionics earned a news impact score of 0.13 on Accern's scale. They also gave media stories about the company an impact score of 46.76 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Ekso Bionics?
Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ekso Bionics' stock price today?
One share of EKSO stock can currently be purchased for approximately $1.7590.
How big of a company is Ekso Bionics?
Ekso Bionics has a market capitalization of $106.16 million and generates $7.35 million in revenue each year. The company earns $-29,120,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Ekso Bionics employs 92 workers across the globe.
How can I contact Ekso Bionics?
Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]
MarketBeat Community Rating for Ekso Bionics (NASDAQ EKSO)
MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
